A name can suggest a sharper mind; an experiment has to show its work. We follow Semax, Selank and DSIP from their first design to the human questions still unanswered.
Explore the Semax and Selank blend at Promise PeptidesNeurotech Peptides may earn money when readers become Promise patients.
Neuropeptides are short strings of amino acids, the building blocks also found in proteins, involved in messages between nerve cells. A message can change what another cell does. That description explains a biological role; it does not establish that adding a particular peptide changes a person’s memory or attention.
A short amino-acid sequence forms a peptide signal.
A receiving protein can interact with the molecule.
A cell response still needs a separate test in people.
The three names in this guide have different histories. Semax was designed around a fragment of ACTH, a hormone involved in the stress response. Selank extends tuftsin, a small peptide connected with the immune system. DSIP entered the literature through rabbit experiments on electrical activity during sleep. Shared length is a poor reason to expect shared effects.
Two synthetic seven-part chains with different starting points. The combined product has to be considered separately from the component experiments.
The Semax and Selank preparation is compounded and is not FDA-approved.
Examine the combined product
A nine-part peptide whose early sleep experiments left an enduring biological question. Its specific receptor remains unresolved.
Compounded DSIP is not FDA-approved.
Follow the DSIP investigationThe components deserve separate explanations even though the available blend combines them. Our Semax account follows nerve-cell signaling research; our Selank account follows studies of inhibitory signaling, which reduces the likelihood that a nerve cell sends another electrical message. Neither is a prediction about feeling focused or calm.
Much of the Semax mechanism story comes from rats. A study of BDNF protein, a protein involved in nerve-cell survival and connections, measured changes in one brain region. It did not measure a person’s concentration. Selank research includes laboratory work on GABA, a chemical messenger that usually dampens nerve-cell activity, and small Russian studies of people with anxiety disorders.
DSIP’s descriptive name is particularly easy to overread. A critical research review found major unanswered questions about its biology and weak support for its sleep hypothesis. Our evidence guide separates a laboratory measurement, a patient study and a story posted online. Those are different kinds of information, even when the same compound appears in all three.
Promise Peptides currently connects U.S. patients with licensed U.S. providers who can prescribe peptide treatment. Every request gets an individual review, and some readers will not be eligible for treatment through this service. State and treatment availability differ. When a prescription is issued, licensed U.S. compounding pharmacies prepare the medicine; Promise is the telehealth platform.
These medicines are compounded for prescriptions and are not FDA-approved. The FDA does not review them for safety, effectiveness and quality before marketing. Promise holds LegitScript certification; that certification does not confer FDA approval on a medicine. These distinctions matter more than how familiar a compound’s name sounds.
No. A change in a cell signal needs a separate human test before it can support a claim about daily life. An animal experiment can make a question interesting without answering it for people.
The Promise route described here is the combined Semax and Selank product. The two ingredients are available through Promise together in one product; separate component treatments are not offered through this route.
At the health review. Other medicines, medical history and the gaps in long-term evidence can change a provider’s judgment. The full questions page gives more context for that conversation.
The blend has a prescribing route through Promise Peptides. A licensed U.S. provider weighs the request against the person’s health; a compelling mechanism cannot make that decision.
